Portfolio
Current fund ventures
Explore the projects OPIF has worked with since launching in May 2025 — each one vetted for sustainable growth, long-term value creation, and risk-adjusted return.
Nbryo
An Australian agritech pioneer revolutionising beef and dairy breeding through rapid, scalable embryo transfer technology — compressing 7 years of genetic improvement into 7 days. Backed by the Bill & Melinda Gates Foundation and others.
Implicit Bioscience
A clinical-stage biotech harnessing IC14, a monoclonal antibody that modulates CD14, offering new hope for inflammatory and neurodegenerative conditions. Founded 2005 by immunology pioneer Prof. Ian Frazer.
Anti Ordinary
A Brisbane-based brain protection company pioneering next-generation helmet technology, validated as the safest all-mountain helmet ever tested by the Virginia Tech Helmet Lab.
Artemis Structural Intelligence
A clinical-stage biotech harnessing IC14, a monoclonal antibody that modulates CD14, offering new hope for inflammatory and neurodegenerative conditions. Founded 2005 by immunology pioneer Prof. Ian Frazer.
Pipeline
More opportunities in development
We're actively evaluating additional high-potential ventures aligned with our mission of long-term value and impact. Subscribe for updates as new offerings are announced.
Opportunity-Plus Investment Fund
Connecting institutional, accredited, and high-net-worth investors with carefully vetted opportunities across pharma and agribiotech.
Contact
© 2026 Opportunity-Plus Investment Fund (OPIF). All rights reserved.